Consistent with our patient analysis, analysis of different AML datasets from Oncomine (Supplementary Fig. 4b), TCGA (Supplementary Fig. 4c) and recently published data55 (Supplementary Fig. 4d, e) show that there is an overall trend that HSF1 levels are higher in AML patients than healthy controls and especially higher in AML with poor/complex cytogenetics or adverse outcomes. This evidence concerns the gene HSF1 and acute myeloid leukemia.